A practical reference on Lactam bridge: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
When a uranium nucleus fissions into two daughter nuclei fragments, about 0.1 percent of the mass of the uranium nucleus appears as the fission energy of ~200 MeV. For uranium-235 (total mean fission energy 202.79 MeV), typically ~169 MeV appears as the kinetic energy of the daughter nuclei, which fly apart at about 3% of the speed of light, due to Coulomb repulsion. Also, an average of 2.5 neutrons are emitted, with a mean kinetic energy per neutron of ~2 MeV (total of 4.8 MeV). The fission reaction also releases ~7 MeV in prompt gamma ray photons. The latter figure means that a nuclear fission explosion or criticality accident emits about 3.5% of its energy as gamma rays, less than 2.5% of its energy as fast neutrons (total of both types of radiation ~6%), and the rest as kinetic energy of fission fragments (this appears almost immediately when the fragments impact surrounding matter, as simple heat). Some processes involving neutrons are notable for absorbing or finally yielding energy — for example neutron kinetic energy does not yield heat immediately if the neutron is captured by a uranium-238 atom to breed plutonium-239, but this energy is emitted if the plutonium-239 is later fissioned.
Numerous other side reactions can occur, and these include E/Z isomerization, which can potentially be a problem when an alkenylstannane is utilized. The mechanism of this transformation is currently unknown. Normally, organostannanes are quite stable to hydrolysis, yet when very electron-rich aryl stannanes are used, this can become a significant side reaction.
=== Soundtrack === Most of the soundtrack is non-lyrical ambient music composed by Kelly Bailey and Mike Morasky, somewhat dark and mysterious to match the mood of the environments. The closing credits song, "Still Alive", was written by Jonathan Coulton and sung by Ellen McLain (a classically trained operatic soprano) as the GLaDOS character. A brief instrumental version of "Still Alive" is played in an uptempo Latin style over radios in-game. Wolpaw notes that Coulton was invited to Valve a year before the release of Portal, though it was not yet clear where Coulton would contribute. "Once Kim [Swift] and I met with him, it quickly became apparent that he had the perfect sensibility to write a song for GLaDOS." The use of the song over the closing credits was based on a similar concept from the game God Hand, one of Wolpaw's favorite titles. The song was released as a free downloadable song for the music video game Rock Band on April 1, 2008. The soundtrack for Portal was released as a part of The Orange Box Original Soundtrack. The soundtrack was released in a four-disc retail bundle, Portal 2: Songs To Test By (Collector's Edition), on October 30, 2012, featuring music from both games. The soundtrack was released via Steam Music on September 24, 2014.
Membrane separation processes operate without heating and therefore use less energy than conventional thermal separation processes such as distillation, sublimation, or crystallization. The separation process is purely physical and both fractions (permeate and retentate) can be obtained as useful products. Cold separation using membrane technology is widely used in the food technology, biotechnology and pharmaceutical industries. Furthermore, using membranes enables separations to take place that would be impossible using thermal separation methods. For example, it is impossible to separate the constituents of azeotropic liquids or solutes which form isomorphic crystals by distillation or recrystallization, but such separations can be achieved using membrane technology. Depending on the type of membrane, selective separation of certain individual substances or substance mixtures is possible. Important technical applications include the production of drinking water by reverse osmosis. In waste water treatment, membrane technology is becoming increasingly important. Ultra/microfiltration can be very effective in removing colloids and macromolecules from wastewater. This is needed if wastewater is discharged into sensitive waters especially those designated for contact water sports and recreation. About half of the market is in medical applications such as artificial kidneys to remove toxic substances by hemodialysis and as artificial lung for bubble-free supply of oxygen in the blood.
Sources: en.wikipedia.org
but I may mention that this last conclusion cannot be true except so long as the compressed vapours remain entirely in the elastic state; and this requires that their temperature shall be sufficiently elevated to enable them to resist the pressure which tends to make them assume the liquid state.
== Limitations and means of improvement == The main disadvantage of absorption spectrometry (AS) as well as laser absorption spectrometry (LAS) in general is that it relies on a measurement of a small change of a signal on top of a large background. Any noise introduced by the light source or the optical system will deteriorate the detectability of the technique. The sensitivity of direct absorption techniques is therefore often limited to an absorbance of ~10−3, far away from the shot noise level, which for single pass direct AS (DAS) is in the 10−7 – 10−8 range. Since this is insufficient for many types of applications, AS is seldom used in its simplest mode of operation. There are basically two ways to improve on the situation; one is to reduce the noise in the signal, the other is to increase the absorption. The former can be achieved by the use of a modulation technique, whereas the latter can be obtained by placing the gas inside a cavity in which the light passes through the sample several times, thus increasing the interaction length. If the technique is applied to trace species detection, it is also possible to enhance the signal by performing detection at wavelengths where the transitions have larger line strengths, e.g. using fundamental vibrational bands or electronic transitions.
=== Pharmacodynamics === Mestanolone is an AAS, with both androgenic and anabolic effects. It is very similar in its effects to androstanolone (dihydrotestosterone; DHT), and can be thought of as an orally active version of this AAS. Due to inactivation by 3α-hydroxysteroid dehydrogenase (3α-HSD) in skeletal muscle, mestanolone is described as a very poor anabolic agent, similarly to androstanolone and mesterolone. As mestanolone is 5α-reduced, it cannot be aromatized and hence has no propensity for estrogenic side effects such as gynecomastia. The drug also has no progestogenic activity. Like other 17α-alkylated AAS, mestanolone is hepatotoxic.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.